Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual

Christophe Merceron, Kavitha Ranganathan, Elizabeth Wang, Zachary Tata, Shreya Makkapati, Mohd Parvez Khan, Laura Mangiavini, Angela Qing Yao, Laura Castellini, Benjamin Levi, Amato J. Giaccia, Ernestina Schipani

Research output: Contribution to journalArticle

Abstract

Osteoblasts, which are the bone-forming cells, operate in a hypoxic environment. The transcription factors hypoxia-inducible factor-1α (HIF1) and HIF2 are key mediators of the cellular response to hypoxia. Both are expressed in osteoblasts. HIF1 is known to be a positive regulator of bone formation. Conversely, the role of HIF2 in the control osteoblast biology is still poorly understood. In this study, we used mouse genetics to demonstrate that HIF2 is an inhibitor of osteoblastogenesis and bone mass accrual. Moreover, we provided evidence that HIF2 impairs osteoblast differentiation at least in part, by upregulating the transcription factor Sox9. Our findings constitute a paradigm shift, as activation of the hypoxia-signaling pathway has traditionally been associated with increased bone formation through HIF1. Inhibiting HIF2 could thus represent a therapeutic approach for the treatment of the low bone mass observed in chronic diseases, osteoporosis, or aging.

Original languageEnglish (US)
Article number7
JournalBone Research
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2019
Externally publishedYes

Fingerprint

Osteoblasts
Hypoxia-Inducible Factor 1
Bone and Bones
Osteogenesis
Transcription Factors
Osteoporosis
Chronic Disease
endothelial PAS domain-containing protein 1
Hypoxia
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Histology
  • Physiology

Cite this

Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual. / Merceron, Christophe; Ranganathan, Kavitha; Wang, Elizabeth; Tata, Zachary; Makkapati, Shreya; Khan, Mohd Parvez; Mangiavini, Laura; Yao, Angela Qing; Castellini, Laura; Levi, Benjamin; Giaccia, Amato J.; Schipani, Ernestina.

In: Bone Research, Vol. 7, No. 1, 7, 01.12.2019.

Research output: Contribution to journalArticle

Merceron, C, Ranganathan, K, Wang, E, Tata, Z, Makkapati, S, Khan, MP, Mangiavini, L, Yao, AQ, Castellini, L, Levi, B, Giaccia, AJ & Schipani, E 2019, 'Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual', Bone Research, vol. 7, no. 1, 7. https://doi.org/10.1038/s41413-019-0045-z
Merceron, Christophe ; Ranganathan, Kavitha ; Wang, Elizabeth ; Tata, Zachary ; Makkapati, Shreya ; Khan, Mohd Parvez ; Mangiavini, Laura ; Yao, Angela Qing ; Castellini, Laura ; Levi, Benjamin ; Giaccia, Amato J. ; Schipani, Ernestina. / Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual. In: Bone Research. 2019 ; Vol. 7, No. 1.
@article{7770064883ae4a149478200088fb997c,
title = "Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual",
abstract = "Osteoblasts, which are the bone-forming cells, operate in a hypoxic environment. The transcription factors hypoxia-inducible factor-1α (HIF1) and HIF2 are key mediators of the cellular response to hypoxia. Both are expressed in osteoblasts. HIF1 is known to be a positive regulator of bone formation. Conversely, the role of HIF2 in the control osteoblast biology is still poorly understood. In this study, we used mouse genetics to demonstrate that HIF2 is an inhibitor of osteoblastogenesis and bone mass accrual. Moreover, we provided evidence that HIF2 impairs osteoblast differentiation at least in part, by upregulating the transcription factor Sox9. Our findings constitute a paradigm shift, as activation of the hypoxia-signaling pathway has traditionally been associated with increased bone formation through HIF1. Inhibiting HIF2 could thus represent a therapeutic approach for the treatment of the low bone mass observed in chronic diseases, osteoporosis, or aging.",
author = "Christophe Merceron and Kavitha Ranganathan and Elizabeth Wang and Zachary Tata and Shreya Makkapati and Khan, {Mohd Parvez} and Laura Mangiavini and Yao, {Angela Qing} and Laura Castellini and Benjamin Levi and Giaccia, {Amato J.} and Ernestina Schipani",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41413-019-0045-z",
language = "English (US)",
volume = "7",
journal = "Bone Research",
issn = "2095-4700",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual

AU - Merceron, Christophe

AU - Ranganathan, Kavitha

AU - Wang, Elizabeth

AU - Tata, Zachary

AU - Makkapati, Shreya

AU - Khan, Mohd Parvez

AU - Mangiavini, Laura

AU - Yao, Angela Qing

AU - Castellini, Laura

AU - Levi, Benjamin

AU - Giaccia, Amato J.

AU - Schipani, Ernestina

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Osteoblasts, which are the bone-forming cells, operate in a hypoxic environment. The transcription factors hypoxia-inducible factor-1α (HIF1) and HIF2 are key mediators of the cellular response to hypoxia. Both are expressed in osteoblasts. HIF1 is known to be a positive regulator of bone formation. Conversely, the role of HIF2 in the control osteoblast biology is still poorly understood. In this study, we used mouse genetics to demonstrate that HIF2 is an inhibitor of osteoblastogenesis and bone mass accrual. Moreover, we provided evidence that HIF2 impairs osteoblast differentiation at least in part, by upregulating the transcription factor Sox9. Our findings constitute a paradigm shift, as activation of the hypoxia-signaling pathway has traditionally been associated with increased bone formation through HIF1. Inhibiting HIF2 could thus represent a therapeutic approach for the treatment of the low bone mass observed in chronic diseases, osteoporosis, or aging.

AB - Osteoblasts, which are the bone-forming cells, operate in a hypoxic environment. The transcription factors hypoxia-inducible factor-1α (HIF1) and HIF2 are key mediators of the cellular response to hypoxia. Both are expressed in osteoblasts. HIF1 is known to be a positive regulator of bone formation. Conversely, the role of HIF2 in the control osteoblast biology is still poorly understood. In this study, we used mouse genetics to demonstrate that HIF2 is an inhibitor of osteoblastogenesis and bone mass accrual. Moreover, we provided evidence that HIF2 impairs osteoblast differentiation at least in part, by upregulating the transcription factor Sox9. Our findings constitute a paradigm shift, as activation of the hypoxia-signaling pathway has traditionally been associated with increased bone formation through HIF1. Inhibiting HIF2 could thus represent a therapeutic approach for the treatment of the low bone mass observed in chronic diseases, osteoporosis, or aging.

UR - http://www.scopus.com/inward/record.url?scp=85061802340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061802340&partnerID=8YFLogxK

U2 - 10.1038/s41413-019-0045-z

DO - 10.1038/s41413-019-0045-z

M3 - Article

VL - 7

JO - Bone Research

JF - Bone Research

SN - 2095-4700

IS - 1

M1 - 7

ER -